AZ Dyrk1B 33
Potent and selective ATP-competitive Dyrk1B kinase inhibitor (IC50 = 7 nM); displays distinct cellular effects when compared to DYRK1B knockdown through siRNA. Demonstrates cellular in vitro activity (IC50 = 194 nM). Exhibits better selectivity than AZ 191 (Cat. No 5232); displays no off-target effects against a panel of 124 kinases tested (no kinase was inhibited above 50% at 1 μM).
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 300.36. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.33 mL||16.65 mL||33.29 mL|
|5 mM||0.67 mL||3.33 mL||6.66 mL|
|10 mM||0.33 mL||1.66 mL||3.33 mL|
|50 mM||0.07 mL||0.33 mL||0.67 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Kettle et al (2015) Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis. J.Med.Chem. 58 2834 PMID: 25738750
If you know of a relevant reference for AZ Dyrk1B 33, please let us know.
View Related Products by Product Action
Keywords: AZ Dyrk1B 33, supplier, AZDyrk1B33, Dyrk1B, kinase, inhibitors, inhibits, dual, specificity, tyrosine, phosphorylation, regulated, kinases, potent, DYRK, Tocris Bioscience
Citations for AZ Dyrk1B 33
Citations are publications that use Tocris products.
Currently there are no citations for AZ Dyrk1B 33. Do you know of a great paper that uses AZ Dyrk1B 33 from Tocris? If so please let us know.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.